A Patent Analytics Report on the Australian Research Sector

May 2016
Copyright
All content in this publication is provided under a Creative Commons Attribution 4.0 International (CC BY 4.0) licence. http://creativecommons.org/licenses/by/4.0/ with the exception of:
- the Commonwealth Coat of Arms,
- IP Australia’s corporate logo
- photographs of our staff and premises
- content provided by third parties – including photographs, logos, drawings and written descriptions of patents and designs

Third party copyright
IP Australia has made all reasonable efforts to:
- clearly label material where the copyright is owned by a third party
- ensure that the third party has consented to this material being presented in this publication.
Permission may need to be obtained from third parties to re-use their material.
© Commonwealth of Australia 2016

Attribution
The CC BY licence is a standard form licence agreement that allows you to copy and redistribute the material in any medium or format, as well as remix, transform, and build upon the material, on the condition that you provide a link to the licence, you indicate if changes were made, and you attribute the material as follows:

Licensed from the Commonwealth of Australia under a Creative Commons Attribution 4.0 International Licence.

Contact us (www.ipaustralia.gov.au) if you have any enquiries about IP Australia’s copyright licence or the use of material in this publication.

Enquiries
National Patent Analytics Hub
Email: analytics@ipaustralia.gov.au

Disclaimer
The information contained in this brief has been gathered from global intellectual property (IP) databases and represents a snapshot of IP rights in the Australian Research sector at a particular point in time. It is provided for general information only and should not be relied upon for the purposes of any particular matter. It is not a report on patentability or freedom to operate and should not be relied upon for those purposes.
Contents

Glossary ........................................................................................................................................... 5

1 Introduction .................................................................................................................................. 6
  1.1 IP Rights .................................................................................................................................. 6
    1.1.1 Patents .................................................................................................................................. 6
    1.1.2 Trade marks ......................................................................................................................... 7
    1.1.3 Designs .................................................................................................................................. 7
    1.1.4 Plant Breeder’s Rights .......................................................................................................... 7
  1.2 Intellectual property as an indicator of research performance .............................................. 7
  1.3 Databases .................................................................................................................................. 8
  1.4 Who is this report about? .......................................................................................................... 8
  1.5 Time frame for analysis ........................................................................................................... 9
  1.6 Methodology ............................................................................................................................. 9

2 Analysis of patents over time ...................................................................................................... 10
  2.1 Comparison of provisional and PCT applications ................................................................... 10
  2.2 Universities ............................................................................................................................. 10
  2.3 Publicly Funded Research Agencies ....................................................................................... 10
  2.4 Medical Research Institutes ...................................................................................................... 12
  2.5 Target Markets ........................................................................................................................ 12
  2.6 Granted Applications ................................................................................................................ 14

3 Patent Applicants ........................................................................................................................ 15
  3.1 Top Patent Applicants .............................................................................................................. 15
  3.2 Patent Holdings ........................................................................................................................ 16
  3.3 Collaboration ............................................................................................................................ 18

4 Looking at Technology ................................................................................................................ 20
  4.1 Technology ............................................................................................................................... 20
  4.2 Relative Specialisation Index (RSI) ......................................................................................... 21
  4.3 Citation analysis ....................................................................................................................... 22

5 Other Intellectual Property Rights ............................................................................................. 26
  5.1 Trade marks ............................................................................................................................. 26
  5.2 Designs ...................................................................................................................................... 28
  5.3 Plant Breeder’s Rights ............................................................................................................. 28

6 Conclusion ..................................................................................................................................... 30

Appendix A: Research Organisations ............................................................................................ 31
Appendix B: Data sources ................................................................. 33
IPGOD .................................................................................................. 33
PSS  33
PATSTAT .......................................................................................... 33
INPADOC .......................................................................................... 33
OECD Citations Database ................................................................. 33
Appendix C: Methodology .................................................................. 35
Identification of research organisations .............................................. 35
Patent data ....................................................................................... 36
Other IP rights data .......................................................................... 38
**Glossary**

<table>
<thead>
<tr>
<th>ABN</th>
<th>Australian business number</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADC</td>
<td>Australian designs classification</td>
</tr>
<tr>
<td>AIMS</td>
<td>Australian Institute of Medical Scientists</td>
</tr>
<tr>
<td>ANSTO</td>
<td>Australian Nuclear Research and Development Organisation</td>
</tr>
<tr>
<td>ATN</td>
<td>Australian Technology Network</td>
</tr>
<tr>
<td>CSIRO</td>
<td>Commonwealth Scientific and Industrial Research Organisation</td>
</tr>
<tr>
<td>DOCDB</td>
<td>EPO master documentation database</td>
</tr>
<tr>
<td>DSTO</td>
<td>Defence Science and Technology Organisation</td>
</tr>
<tr>
<td>EPO</td>
<td>European Patent Office</td>
</tr>
<tr>
<td>Go8</td>
<td>Group of Eight universities</td>
</tr>
<tr>
<td>HAN</td>
<td>OECD harmonised applicants’ names</td>
</tr>
<tr>
<td>INPADOC</td>
<td>EPO worldwide legal status database</td>
</tr>
<tr>
<td>IP</td>
<td>Intellectual Property</td>
</tr>
<tr>
<td>IPC</td>
<td>International Patent Classification</td>
</tr>
<tr>
<td>IPGOD</td>
<td>Intellectual Property Government Open Data</td>
</tr>
<tr>
<td>MRI</td>
<td>Medical research institute</td>
</tr>
<tr>
<td>NCL</td>
<td>Nice classification</td>
</tr>
<tr>
<td>NICTA</td>
<td>National ICT Australia</td>
</tr>
<tr>
<td>NPE</td>
<td>National-Phase Entry</td>
</tr>
<tr>
<td>NSRC</td>
<td>National Survey of Research Commercialisation</td>
</tr>
<tr>
<td>PATSTAT</td>
<td>EPO worldwide patent statistical database</td>
</tr>
<tr>
<td>PBR</td>
<td>Plant breeder’s right</td>
</tr>
<tr>
<td>PCT</td>
<td>Patent Cooperation Treaty</td>
</tr>
<tr>
<td>PFRO</td>
<td>Publicly Funded Research Organisation</td>
</tr>
<tr>
<td>PFRA</td>
<td>Publicly Funded Research Agency</td>
</tr>
<tr>
<td>PSS</td>
<td>Internal IP Australia administrative data</td>
</tr>
<tr>
<td>QIMR</td>
<td>Queensland Institute of Medical Research</td>
</tr>
<tr>
<td>RSI</td>
<td>Relative Specialisation Index</td>
</tr>
<tr>
<td>UQ</td>
<td>University of Queensland</td>
</tr>
<tr>
<td>WEHI</td>
<td>Walter and Eliza Hall Institute of Medical Research</td>
</tr>
<tr>
<td>WIPO</td>
<td>World Intellectual Property Organization</td>
</tr>
</tbody>
</table>
1 Introduction

This report analyses the intellectual property (IP) rights holdings of publically funded research organisations (PFROs) in Australia and provides an overview of innovation originating from the Australian research sector. These organisations take part in the National Survey of Research Commercialisation (NSRC). In 2014–15 the survey was reviewed to help strengthen and streamline the data collection, and to ensure the survey aligns with current and emerging objectives for research commercialisation in Australia and abroad. As part of data collection streamlining and reducing the burden upon survey respondents, the Patent Analytics Hub at IP Australia extracted IP data related to the PFROs. This data covers four IP rights governed by IP Australia—patents, trade marks, designs and plant breeders rights.

The purpose of the report is twofold: to provide benchmark metrics on the current state of the commercialisation practices of the research sector; and to provide examples of metrics that could be used to gain a greater understanding of impact.

This report is a follow-up to the 2013 report “Research Performance of University Patenting in Australia: A Pilot Assessment”. Compared with the previous report, which included only 12 universities, this report has a greater scope, updated metrics and an explanation of why we have chosen not to pursue some previously used methods of analysis.

1.1 IP Rights

1.1.1 Patents

A patent is a right that is granted for any device, substance, method or process that is new, inventive and useful. Australian patent rights are legally enforceable and give the owner exclusive rights to commercially exploit the invention for a period of up to 20 years.

Provisional applications are normally the first step in applying for a standard or an innovation patent and establish a priority date for the invention. A provisional patent application is not examined and is not an enforceable right, but allows applicants 12 months to determine if they will seek further patent protection for their invention.

If further protection is sought there are two major filing routes for patent applications: international and direct.

The international route involves filing a Patent Cooperation Treaty (PCT) application, which establishes a filing date in all 148 contracting states. A PCT application allows preliminary examination of a patent application, but also provides time for the applicant to defer large costs while assessing the viability of the invention disclosed in the patent application. In order to secure patent rights in any given country, an applicant must lodge individual applications in countries, referred to as national-phase entry (NPE). A PCT application must enter the national phase to proceed towards grant. A patent can only be enforced once it has been granted. It is necessary to pay fees to each country in which patent protection is sought.

Direct, or convention applications, are only lodged in the countries of interest. These applications will be examined before proceeding to grant. After grant, the patent may be enforced.

Applications generally relating to the same invention but lodged in different countries are known as patent families. Patent families enable us to analyse inventive activity regardless of the number of countries in which protection is sought. We use patent families according to the INPADOC patent

---

1. IP Australia, Research Performance of University Patenting in Australia: A Pilot Assessment, 2013
2. WIPO, List of PCT Contracting States
family definition. An INPADOC patent family is defined as comprising all the documents sharing directly or indirectly (e.g. via a third document) at least one priority. This includes all the patent documents resulting from a patent application submitted as a first application with a patent office and from the same patent application in any country.3

1.1.2 Trade marks

A trade mark is a right that is granted for a letter, number, word, phrase, sound, smell, shape, logo, picture and/or aspect of packaging. It is a distinctive sign that identifies a product or service. A registered trade mark is legally enforceable and gives the owner exclusive rights to commercially use, license or sell it for the goods and services under which it is registered. The holder of the trade mark can prevent unauthorised use of the trade mark or a confusingly similar mark, so as to prevent consumers and the general public from being misled. Trade mark registration can be extended indefinitely, as long as it is in use. Trade marks can be associated with both high- and low-technology products.

1.1.3 Designs

Industrial designs protect the appearance of products which have industrial or commercial use. A design specifically refers to the features of shape, configuration, pattern or ornamentation which give a product a unique appearance, and must be new and distinctive. Industrial designs are broad and cover many sectors including digital media, fashion design, furniture design, graphic design and textile design.

Design rights are only enforceable once examined and certified. A certified design gives the owner the exclusive right to commercially use, licence or sell their design. The maximum term for design protection is 10 years.

1.1.4 Plant Breeder’s Rights

A plant breeder’s right (PBR) is a legally enforceable registration which provides its owner with the exclusive right to commercially produce, propagate, use, sell or distribute a new plant variety. The variety must be new, exploited within the past 12 months or derived from directly from an existing protected varietal.4 PBR protection of the varietal is for a period of 25 years from the date of grant.

1.2 Intellectual property as an indicator of research performance

Each IP right can be used as an indicator of research and innovation, although they reflect differing aspects.5 Patents and plant breeder’s rights (PBRs) are more likely to reflect a significant technological innovation, whereas a trade mark or design is more likely to reflect a product coming to market.

It is a requirement of patent law that patent documents are published and that they fully disclose inventions. As a result of the disclosure requirement, patent documents reflect developments in science and technology. Patent documents include other useful information, such as International Patent Classification (IPC) marks, and information about inventors and applicants.

3 European Patent Office, Patent families
4 IP Australia, Plant Breeder’s Rights
Through the extraction and analysis of data associated with patent documents, it is possible to measure aspects of inventive activity such as scope, intensity, collaboration and impact. These metrics can be developed across technology sectors and by various units of measurement, such as individuals (inventors), institutions (applicants), regions and countries.

Similarly, a PBR may be used as an indicator of research and innovation in plants. Once an application for a PBR is finalised, the application data and a photograph are published. This data, together with the plant’s end use classification information provide and insight into edible and non-edible plant developments.

Trade marks and designs data are also published and, like patents, can provide information about applicants and technology areas. Whilst patents are proxies for innovation in high-technology industries, they are not necessarily associated with innovation in low-technology industries, or industries that have a high product turnover. In these industries, such as clothing or furniture, trade marks and designs may be more relevant markers of innovation.

1.3 Databases

The data was compiled from the following sources:

- **EPO Worldwide Patent Statistical Database** (PATSTAT), European Patent Office, Spring 2015 edition. PATSTAT is a snapshot of statistics relating to the EPO master documentation database (DOCDB) with worldwide coverage, containing 20 tables including bibliographic data, citations and family links. It is designed to be used for statistical research.

- **Intellectual Property Government Open Data** (IPGOD), IP Australia, 2015 edition. IPGOD is the database of IP Rights administered by IP Australia comprising patents, trademarks, designs and plant breeders’ rights, linked by applicant and which is matched to firm level data including Australian Business numbers, geocoding and firm size.

- Internal IP Australia administrative data (PSS), accessed October 2015. Unlike IPGOD, which is a publicly available extract of IP Australia data, PSS is an internal database of all of IP Australia’s administrative data relating to IP rights. PSS is not publicly available.

- **EPO worldwide legal status database** (INPADOC), European Patent Office, Spring 2015 edition. INPADOC contains information on legal events that occurred during the life of a patent, either before or after grant.

- OECD citations database, which provides information on patent and non-patent literature citations found in patent documents.  

A more detailed explanation of the databases can be found in Appendix B.

1.4 Who is this report about?

This report covers the IP rights for a range of Australian PFROs. There are 40 universities, 52 medical research institutes (MRIs) and five publicly funded research agencies (PFRAs) included in our analysis. For the purposes of this report, controlled entities were not included, with the exception of technology transfer offices associated with universities. Hospitals were not included in the list of MRIs. A full list of the applicants that were included is provided in Appendix A.

---


1.5 Time frame for analysis

Intellectual property rights with an application or lodgement date between 1 January 2000 and 31 December 2014 were used in this analysis. We used application date, the date on which a patent application is received by an office, for the time series graphs as this coincides with how the NSRC data is presented. Another relevant method for presenting time series is data is by the earliest priority date (EPD). This represents the first time that a patent application for a particular invention has been lodged anywhere in the world.

1.6 Methodology

The first step was to capture as many variations as possible of applicant names which were provided as NSRC survey recipients. These names, as well as any ABN information, later formed the basis of our search strategy for the identification of IP rights applicants in the various IP rights databases referenced above. In the case of universities this also includes their technology transfer offices. A full description of the methodology used to capture IP rights records that form the data set is included in Appendix C.
2 Analysis of patents over time

2.1 Comparison of provisional and PCT applications

Provisional and PCT applications can be viewed as a proxy for inventions and the beginning of the process that can lead to commercialisation. Figures 1-3 show a comparison of provisional patent applications over time compared to PCT applications based on application year for each group of research organisations: universities, publicly funded research agencies and medical research institutes (MRIs). This metric requires combining data from IP Australia's patent administration database (PSS), which records provisional patent filings, with PCT applications from the PATSTAT database and comparing the two different application types to gain an understanding of the patenting strategies employed by the three sectors.

We have chosen to plot the metric on application year, however earliest priority year can also be used for PCT applications. It is the earliest date recorded on patents and therefore allows the comparison of dates unaffected by administrative variations or delays.

It should be noted that there may not be a one-to-one link between provisional applications and PCTs. Not all provisional applications result in a PCT application, as some may have gone through the convention route or been allowed to lapse. Convention applications make up a small percentage of international applications. In addition, some PCT applications may be based on more than one provisional application or on provisional applications filed in other jurisdictions. For the PCT applications analysed below, between 5 and 20 per cent had priority applications from jurisdictions other than Australia each year.

2.2 Universities

The university sector shown in Figure 1 lodged a total of 4363 provisional applications and 2429 PCT applications from 2000–14. There has been a small, but gradual increase in the number of PCT applications over the period. Peaks in provisional applications generally precede an increase in PCT applications, suggesting that applying provisional patent applications followed by a PCT application is a conventional filing strategy.

Given the difference in the numbers of provisional and PCT applications, Figure 1 suggests that universities, as a whole when compared to PFRAs and MRIs, are more likely to lodge a provisional in order to buy time to explore the value of the invention. This is perhaps not surprising, as most inventions from the sector are at a very early stage and it difficult to predict commercial interest that stage of development.

2.3 Publicly Funded Research Agencies

Figure 2 shows the same comparison for the publicly funded research agencies (PFRAs). Over the period they lodged 1715 provisional applications and 1026 PCT applications. The majority of these applications were field by the Commonwealth Scientific and Industrial Research Organisation (CSIRO), with approximately 80 per cent of PCT applications and 83 per cent of provisional applications. Since a peak in provisional applications in 2005 there has been a decrease, whilst the numbers of PCT applications have remained steady. This may represent a change in approach to patenting by PRFAs, for example where provisional patent applications are lodged only when it is likely that further patent protection will be pursued.
Figure 1: University provisional applications vs PCT applications

Source: PATSTAT Spring edition 2015 and IP Australia's internal patent administration database

Figure 2: PFRA provisional applications vs PCT applications

Source: PATSTAT Spring edition 2015 and IP Australia's internal patent administration database
2.4 Medical Research Institutes

Figure 3 shows that the Medical Research Institutes (MRIs) file similar numbers of provisional applications (501 applications) and PCT applications (481 applications). This patenting strategy is different to the universities who appear to file a large amount of provisional applications protecting any potential IP and then selecting only the most valuable of these inventions to file through the PCT route. When compared to PFRAs, the 52 MRIs file only half as many of each type of patent applications.

**Figure 3: MRI provisional applications vs PCT applications**

![Chart showing MRI provisional applications vs PCT applications]

Source: PATSTAT Spring edition 2015 and IP Australia's internal patent administration database

2.5 Target Markets

In order to look at target markets of the inventions, we can look at the countries where research organisations in Australia elect to enter national phase.

The filing breadth for each of the research sectors is shown in Figure 4. Australia, the United States and Europe are the top three filing locations for all of the research sectors. China and South Korea also feature prominently. Japan, although a large market, does not make the top ten countries for any sector. The results in individual European countries represent member state patents which are generated when a European application is granted. Europe is a major filing destination, but once a patent is granted by the European Patent Office, the applicant must choose which countries to enter to gain an enforceable patent right. The major European markets are Germany, Austria and Spain. Brazil also appears as a target market for both universities and PFRAs.
Figure 4: Target markets

Source: PATSTAT Spring edition 2015
2.6 Granted Applications

Figure 5 shows the breakdown of granted patents, lapsed applications without grant and pending applications that have entered national phase across the research sector. There are no major differences between the sectors, with approximately 20 per cent of patents being granted and approximately 35 per cent lapsing without grant. The remaining applications are pending, which is due to the time it takes from entering national phase in a country to completing prosecution. This can take up to 5 years. The low percentage of applications proceeding to grant may highlight that the research sector is reliant on finding commercial partners for their inventions. Renewal fees across multiple jurisdictions are expensive and inventions are may be dropped if there is no commercial interest or that the invention is not commercially viable. Another reason that an application may be allowed to lapse is that it is not able to meet the legal criteria for grant.

Figure 5: Summary of application status by sector

![Figure 5: Summary of application status by sector]

Source: PATSTAT Spring edition 2015
3 Patent Applicants

3.1 Top Patent Applicants

The top applicants over the period 2000–14 are shown for each of the research sectors, based on number of patent families. A patent family is made up of applications generally relating to the same invention but lodged in different countries. We used the INPADOC definition of a patent family. Using patent families provides an indication of the applicants that have the most patents in their research sectors without including any bias caused by an applicant applying for a patent for one invention in a large number of countries.

Figure 6 shows the top universities applicants. The majority of top university applicants are from the Group of Eight (Go8) universities, with the first non-Go8 applicant in sixth (the University of Newcastle). The University of South Australia is the first Australian Technology Network (ATN) University on the list in tenth place. ATN universities aim to be 'agile and innovative' in their approach to research and collaboration. The other members of the ATN include RMIT University, The University of Technology Sydney, University of South Australia and Curtin University.

Figure 6: Top university applicants

<table>
<thead>
<tr>
<th>University</th>
<th>Number of patent families</th>
</tr>
</thead>
<tbody>
<tr>
<td>The University of Queensland</td>
<td>400</td>
</tr>
<tr>
<td>The University of Sydney</td>
<td>350</td>
</tr>
<tr>
<td>Monash University</td>
<td>300</td>
</tr>
<tr>
<td>The University of New South Wales</td>
<td>250</td>
</tr>
<tr>
<td>The University of Melbourne</td>
<td>200</td>
</tr>
<tr>
<td>The University of Newcastle</td>
<td>150</td>
</tr>
<tr>
<td>The Australian National University</td>
<td>100</td>
</tr>
<tr>
<td>The University of Adelaide</td>
<td>50</td>
</tr>
<tr>
<td>The University of Western Australia</td>
<td>25</td>
</tr>
<tr>
<td>University of South Australia</td>
<td>15</td>
</tr>
</tbody>
</table>

Source: PATSTAT Spring edition 2015

The CSIRO dominates the PFRAs for the number of patent families, all of which are shown in Figure 7. This is unsurprising since the CSIRO is one of world’s largest applicants of patents within the government sector. National ICT Australia (NICTA), the Australian Nuclear Research and Development Organisation (ANSTO), Defence Science and Technology Organisation (DSTO) and the Australian Institute of Medical Scientists (AIMS) have a combined total of 234 patent families. NICTA is a technology research institute specialising in computer vision, machine learning, mobile systems, optimisation technology and software systems. NICTA recently merged with CSIRO to create Data61. This was after the time period for this report, which is why they appear as separate entities.

8 Australian Technology Network, About us
10 Thomson Reuters, The Top 25 Global Innovators Government
11 DSTO is now called the Defence Science and Technology Group (DST Group)
12 NICTA, About NICTA
For the MRIs, the Walter and Eliza Hall Institute for Medical Research (WEHI) is the largest applicant, having 85 more patent families than the second largest applicant, the Garvan Institute of Medical Research (Figure 8). WEHI is Australia's oldest research institute and performs research into the prevention and treatment of various diseases including cancer, type 1 diabetes, arthritis and malaria. The Garvan Institute of Medical Research, the second largest MRI applicant, focuses on the understanding of genes and cellular processes for the treatment or prevention of diseases including cancer, diabetes and neurological disorders.

### 3.2 Patent Holdings

For each of the top applicants in each sector, patent families with at least one granted patent still in force (patent renewal fees have been paid) were determined. The payment of renewal fees to keep a patent in force is an indicator of the value of that patent to the applicant. The summary of the in force patent families for each of the top applicants is shown in Figure 9 (universities), Figure 10 (PFRAs) and Figure 11 (MRIs).

---

13 Walter and Eliza Hall Institute, About
14 Garvan Institute, About Us
In Figure 9, the University of Queensland (UQ) and the University of Sydney have the largest number of in force patents families with 161 and 151, respectively. The list generally follows the total numbers of patent families ranking seen in Figure 6, although the Australian National University has more in force patent families than Monash University and the University of Newcastle despite those institutions filing more patent families.

**Figure 9: In-force patent holdings for universities**

![Diagram showing number of in force patent families for universities]

<table>
<thead>
<tr>
<th>University</th>
<th>Number of Patent Families</th>
</tr>
</thead>
<tbody>
<tr>
<td>The University of Queensland</td>
<td>140</td>
</tr>
<tr>
<td>The University of Sydney</td>
<td>151</td>
</tr>
<tr>
<td>The University of Melbourne</td>
<td>120</td>
</tr>
<tr>
<td>The University of New South Wales</td>
<td>161</td>
</tr>
<tr>
<td>The Australian National University</td>
<td>101</td>
</tr>
<tr>
<td>Monash University</td>
<td>90</td>
</tr>
<tr>
<td>The University of Newcastle</td>
<td>80</td>
</tr>
<tr>
<td>The University of Adelaide</td>
<td>60</td>
</tr>
<tr>
<td>The University of Western Australia</td>
<td>40</td>
</tr>
<tr>
<td>University of South Australia</td>
<td>20</td>
</tr>
</tbody>
</table>

Source: PATSTAT Spring Edition 2015

Figure 10 shows granted, in force patent families for PFRAs. As expected, the CSIRO is the top applicant with 493 in force patent families. ANSTO has 66 in force patent families and NICTA has 31.

**Figure 10: In-force patent holdings for PFRAs**

![Diagram showing number of in force patent families for PFRAs]

Source: PATSTAT Spring edition 2015

Finally, the granted, in force patent families for MRIs is shown in Figure 11. WEHI leads the way with 50 in force patent families. QIMR, the Brian Holden Vision Institute and the Florey Institute are also major players.
3.3 Collaboration

One powerful component of the analysis of patent data is the ability to identify research partners collaborating on various inventions. Collaboration in this report is approximated by patent applications with two or more applicants.

Figure 12 shows the percentage of PCT applications with more than one applicant versus applications with a single applicant. All of the research sectors have similar levels of co-applicants, with between 23 and 25 per cent of applications having co-applicants. This includes university-university collaboration as well as university-industry collaboration. It should be noted that this is only a measure of a specific type of collaboration, other forms of knowledge transfer and links between entities are not represented, hence this may underestimate the total interactions that occur between entities.

Countries collaborating with Australian research institutes can be measured by identifying Australian PCT applications listing more than one applicant and examining the country of origin of the other co-applicants. This distribution is shown in Figure 13. Mostly collaboration occurs domestically with 773 applications having Australian co-applicants (not shown). The top foreign applicants are from the United States followed by Switzerland, Japan, Great Britain and France.
Figure 13: Collaboration with Australian applicants

Source: PATSTAT Spring edition 2015
4 Looking at Technology

4.1 Technology

Figure 14 represents a breakdown of all Australian PCT applications filed between 1 January 2000 and 31 December 2014 by WIPO technology field. WIPO technology fields provide a broad technology categorisation that each correspond to a series of IPC marks. Medical technology, civil engineering and pharmaceuticals and computer technology are the main technology areas.

**Figure 14: Technology breakdown of all Australian applicants**

<table>
<thead>
<tr>
<th>Medical technology</th>
<th>Civil engineering</th>
<th>Pharmaceuticals</th>
<th>Computer technology</th>
<th>Furniture or games</th>
<th>Other special machines</th>
<th>Chemical engineering</th>
<th>Transport</th>
<th>Measurement</th>
<th>Other consumer goods</th>
</tr>
</thead>
</table>

![Graph showing technology breakdown of Australian applicants](image)

Source: PATSTAT Spring edition 2015

Figure 15 is a similar technology breakdown for the research institutions. Similar to all Australian applicants', pharmaceuticals and medical devices are a strong area of focus. It should be noted that pharmaceuticals is bolstered by the MRIs, whose major patent focus is in that area, though the universities and PFRAs also contribute to pharmaceuticals significantly. Civil engineering, furniture and games and transport all rank highly outside of the research sector but are not areas of focus within the research sector. Conversely universities, PFRAs and MRIs are more strongly focussed on biotechnology, materials and metallurgy and organic fine chemistry.

---

### 4.2 Relative Specialisation Index (RSI)

The Relative Specialisation Index (RSI) is a metric used to determine how specialised a particular research organisation is in a particularly WIPO technology field. WIPO Technology fields are broad groupings which map patent classifications to technology clusters which are more easily comprehended. Only PCT applications were used to map the technology fields. The RSI is calculated to correct for research organisations that may file more than others. The RSI compares the fraction of technology patents from a particular university compared to fraction of patents originating from Australian applicants overall. The formula used is as follows:

\[
RSI = \log_{10}\left(\frac{\frac{n_i}{N_i}}{\frac{n_{total}}{N_{total}}}\right)
\]

where:

- \(n_i\) is the number of patent applications filed in technology area \(X\) by research organisation \(A\)
- \(n_{total}\) is the number of patent applications filed in technology area \(X\) by all research organisations
- \(N_i\) the total number of patent applications filed in technology area \(X\) by all research organisations
- \(N_{total}\) is the total number of patents applications filed by all research organisations

The effect of this metric is to demonstrate which technology areas a research organisation specialises compared to their peers. When a number is relatively largely positive (closer to 1) then this would imply that comparatively, a large amount of work in this area is done by that organisation, compared to other research organisations. If the number is strongly negative (closer to -1) then comparatively the research organisation files less applications in in this technology area.

A representative example of an RSI for a single organisation (CSIRO) is shown in Figure 16. Figure 16 shows some of the relative technology strengths of CSIRO including materials and metallurgy, biotechnology, and optics. A caveat of using the RSI is that areas with few patents can be seen to be overly positive. For example, the CSIRO is strongly positive in Audio-visual technology, but has only 4 patents in the area. There are only 8 total patents in Audio-visual technology in the entire sector. In comparison, the CSIRO has 46 patents in materials and metallurgy (RSI score of 0.211), but the technology is a more active area of research for the sector as a whole with 110 patents.
To begin a discussion of the value of using citations as a metric, it is important to define what is meant by a patent citation. In academia, a citation represents whether a document was included by the authors as a piece of relevant literature.

For patents, citations are broadly categorised into two types for each patent application: citations to previous documents (backward citations) and citations of the patent application after its publication (forward citations).

Backward citations are taken from the prior art, so refer to information made publicly available before the filing date of a patent application and they are generally relevant to a patent’s claims of novelty or inventive step. Backwards citations can include patent documents and non-patent literature. Forward citations are received by a patent application once it has been published. One of the main difficulties with forward citations is that they can come at any point in time, long after the cited patent was filed, granted, or even reached full term. Therefore, the effect of time...
increases the probability for any patent to have been cited by subsequent patents. A second major difficulty with patent citations relates to the number of publications associated with each single patent.

A citation can be included by both the patent applicant and the examiner. Citations raised by examiners are related to the claims, which change over the course of the examination procedures. They are generally broken into three categories novelty (X), inventive step (Y) and general state of the art (A). Importantly, there is no consistent approach between jurisdictions, nor examiners, on how many relevant documents should be raised. In addition, patent office procedures can change overtime and can also differ between technologies.

Most jurisdictions also have little regulation around which patents are cited by applicants. There can be very few in main body of the patent document and there is no requirement they are particularly close prior art. The exception is the United States, which requires applicants to cite the most relevant documents.17

Some consider that forward citations are a good proxy for the value of a patent.18 However, we hope that the limitations described above have demonstrated the many pitfalls of doing citation analysis. We recommend caution if you are planning to use citation analysis and that attempting to use citations as quantifiable indication of usefulness, importance or novelty is likely to be a very challenging activity.

Nevertheless, an example of a citation analysis is shown in Figure 17. This provides an overview of the number of times PCT applications from Australian research institutions have been cited in either an international (PCT) or European search and examination report.

The distribution is heavily skewed towards the lower end of the scale, with 74 per cent of PCT applications receiving two citations or less and 93 per cent having five citations or less. This skewed distribution and low number of citations makes any useful analysis difficult, as the data becomes very noisy and significantly reduces any confidence in conclusions that can be drawn.

---


Figure 17: Forward citations received by PCT applications from Australian research organisations

Citation analysis can be a useful qualitative measure for highlighting patents which have received a large number of citations and can be considered a measure of impact. This sort of analysis was done in our recent report on Australian Pharmaceutical patents.\(^{19}\) When doing this analysis it is important to group the patents by publication year, as applications tend to receive more citations over time. In this manner a direct comparison between patents with the same publication year can be made, which prevents new patents being swamped by older patents. Figure 18 is an example of a box and whisker plot which can be used to highlight patents with a large number of citations. For example, a PCT application published in 2007 from the CSIRO (WO 2007/015710) stands out as it has received 49 citations, whereas the median citation number of citations for that year is 4.

\(^{19}\) IP Australia (2015), ‘A patent analytics study on the Australian Pharmaceutical Industry’
Figure 18: Forward citations received by Australian research organisation PCT applications, by publication year

Source: OECD Citations September 2015, PATSTAT Spring 2015
5 Other Intellectual Property Rights

5.1 Trade Marks

Trade marks are used to differentiate products and services of one trader from another. Figure 19 represents all of the trade marks applications lodged from 2000–14 for the three research sectors. Applications peaked at 199 in 2008, and have generally remained above 100 per year for the period. There were 1909 total trade marks lodged. In contrast there were 6580 provisional patents and 3939 PCT applications for the research sector over the same period.

Figure 19: Trade mark applications by lodgement year

![Trade mark applications by lodgement year](image)

Source: IPGOD February 2016

Figure 20 shows the top trade mark applicants. CSIRO, with 214 applications, is by far the largest applicant of trade marks. The remaining top five applicants are all universities including the University of Melbourne (123), Macquarie University (111), the University of Queensland (101) and Australian National University (91). The only two MRIs in the top ten are the Brien Holden Vision Institute with 51 applications and the Cancer Council of NSW with 50 applications. The Brien Holden Vision Institute, through collaboration with research and industry organisations, seeks to develop innovative vision correction products for the treatment of most common eye disorders.20 The Cancer Council of NSW helps fund cancer research and supports cancer patients, but is also involved with advocating cancer action and cancer prevention.21 It is important to note this does not include trade mark applications from spin out companies originating from any of these research organisations.

---

20 Brien Holden Vision Institute, [Who we are](#)
21 Cancer Council of NSW, [About us](#)
Under Australian legislation, a single trade mark application may relate to goods or services in one or more of the 45 classes within the Nice Classification system. The top Nice Classification (NCL) descriptors are shown in Figure 21 where multi-class applications are counted multiple times. The type of trade mark protection is primarily in the field of education and entertainment with 1154 applications, representing 60 per cent of the total applications. This is likely the research organisations applying to protect images and 'catch-phrases' which are used to market their respective institutions and highlights a major difference between trade marks and patents. Whilst patents can be considered as markers of innovation, trade marks can be given for both innovative products and for branding purposes. The next largest trade mark area is in is the computer, scientific and legal sector with 883 applications and rounding out the top is three, paper goods and printed matter (481).

Source: IPGOD February 2016

---

22 IP Australia, [Apply for a trade mark: Classes of goods and services](ipaustralia.gov.au/tm/apply-for-a-trademark/).
5.2 Designs

Figure 22 shows the break-down of design applications by research sector. There are very few design applications, a total of only 25, with universities being the largest applicant group. The major university applicant was Monash University with 7 applications. CSIRO lodged 4 design applications and the Murdoch Children’s Research Institute filed the lone design by an MRI for an electrical connector. We used the Australian designs classification (ADC) codes to classify designs. The ADC is substantially the same as the Locarno classification system used internationally. The ADC and Locarno systems can be used interchangeably as they share the common broad classes. The distinction between these two classifications occurs only in the lower subclasses in which the ADC has its own unique alphabetical codes. The top of category for design applications was apparatus and equipment for doctors, hospitals and laboratories (7 applications). No other category had more than 2 applications.

![Figure 22: A break-down of design applications by research sector](image)

Source: IPGOD February 2016

5.3 Plant Breeder’s Rights

A total of 189 plant breeder’s rights (PBR) applications were lodged by research organisations in 2000–14, compared with a total of 5242 PBR applications lodged in Australia over the same period.

CSIRO is the top applicant with 78 applications, as shown in Figure 23. Some of the new plant varieties bred by the CSIRO include cotton, grapes, sugarcane, wheat and barley. The University of Adelaide is ranked second in PBR applications, and with 33 applications has the most PBRs of any of the universities. The University of Adelaide’s Waite Campus specialises in plant breeding, including barley, wheat and faba beans. The University of Sydney ranks third with 25 applications., The University of Sydney’s Plant Breeding Institute concentrates on plant breeding including wheat, mustard and pulse as well as running an environmental and ornamental horticulture program. The remaining universities have lodged fewer than twenty applications each.

---

23 CSIRO, Plant Science
24 University of Adelaide, Plant Breeding
25 University of Sydney, Plant Breeding Institute
Figure 23: Top PBR applicants

Figure 24 shows the type of plants for which protection is being sought. On the whole research organisations are investing in commercial large scale crops, in particular cereals. These type of crops are known in the industry as 'broad-acre'.

Figure 24: PBR applications by plant type

Source: IPGOD Database February 2016 and internal classifications
6 Conclusion

This report provides an overview of the intellectual property landscape for Australian universities, PFRAs and MRIs.

We identified 6580 provisional applications and 3903 PCT applications from the Australian research sector from 2000 to 2014. The major target markets for the inventions, after Australia, were the United States, Europe and Canada. This was consistent across universities, PFRAs and MRIs. China and South Korea are also major target countries.

The organisations have co-applicants on 23-25 percent of applications, which is an indicator of collaboration. The majority (77 percent) are with other Australian applicants. Applicants from the United States are the major foreign collaborators making up 10 per cent of collaborations, followed by Switzerland, Japan and Great Britain.

The top university patent applicants were the University of Queensland, the University of Sydney and Monash University. The CSIRO, the top overall applicant, applied for significantly more patents than the next highest PFRA applicant - NICTA. The top MRI applicants were the Walter and Eliza Hall Institute of Medical Research, the Garvan Institute and the Queensland Institute of Medical Research.

Similar to all Australian applicants', pharmaceuticals and medical devices are a strong area of focus for the research sector. Civil engineering, furniture and games and transport all rank highly outside of the research sector but are not areas of focus within the research sector. Conversely universities, PFRAs and MRIs are more strongly focussed on biotechnology, materials and metallurgy and organic fine chemistry.

The report also highlights caveats and difficulties in using and interpreting some available data—particularly citations.

Research organisations also make use of other intellectual property rights. We identified 1909 trade marks, 25 design applications and 189 plant breeder’s rights.

Trade mark protection is primarily in the field of education and entertainment, representing 60 per cent of the total applications. This is likely the research organisations applying to protect images and 'catch-phrases' which are used to market their respective institutions and highlights a major difference between trade marks and patents. Whilst patents can be considered as markers of innovation, trade marks can be given for both innovative products and for branding purposes.

Plant breeder’s rights are a focus for some of the research organisations. CSIRO is the top PBR applicant, followed by the University of Adelaide and the University of Sydney. These organisations have an interest in developing new commercial scale crops.

The metrics in this report they can be used to provide a greater understanding of the innovation and commercialisation practices of the Australian research sector.
## Appendix A: Research Organisations

### Table 1: Universities

<table>
<thead>
<tr>
<th>University</th>
<th>University</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australian Catholic University</td>
<td>The Australian National University</td>
</tr>
<tr>
<td>Bond University</td>
<td>The University of Adelaide</td>
</tr>
<tr>
<td>Central Queensland University</td>
<td>The University of Canberra</td>
</tr>
<tr>
<td>Charles Darwin University</td>
<td>The University of Melbourne</td>
</tr>
<tr>
<td>Charles Sturt University</td>
<td>The University of New England</td>
</tr>
<tr>
<td>Curtin University of Technology</td>
<td>The University of New South Wales</td>
</tr>
<tr>
<td>Deakin University</td>
<td>The University of Newcastle</td>
</tr>
<tr>
<td>Edith Cowan University</td>
<td>The University of Notre Dame Australia</td>
</tr>
<tr>
<td>Federation University of Australia</td>
<td>The University of Queensland</td>
</tr>
<tr>
<td>Flinders University</td>
<td>The University of South Australia</td>
</tr>
<tr>
<td>Griffith University</td>
<td>The University of Southern Queensland</td>
</tr>
<tr>
<td>James Cook University</td>
<td>The University of Sydney</td>
</tr>
<tr>
<td>La Trobe University</td>
<td>The University of Tasmania</td>
</tr>
<tr>
<td>Macquarie University</td>
<td>The University of the Sunshine Coast</td>
</tr>
<tr>
<td>Monash University</td>
<td>The University of Western Australia</td>
</tr>
<tr>
<td>Murdoch University</td>
<td>The University of Western Sydney</td>
</tr>
<tr>
<td>Queensland University of Technology</td>
<td>The University of Wollongong</td>
</tr>
<tr>
<td>Royal Melbourne Institute of Technology</td>
<td>Torrens University Australia</td>
</tr>
<tr>
<td>Southern Cross University</td>
<td>University of Technology, Sydney</td>
</tr>
<tr>
<td>Swinburne University of Technology</td>
<td>Victoria University of Technology</td>
</tr>
</tbody>
</table>

### Table 2: Medical Research Institutes

<table>
<thead>
<tr>
<th>Medical Research Institute</th>
<th>Medical Research Institute</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Cancer Council of Victoria</td>
<td>Institute For Respiratory Health</td>
</tr>
<tr>
<td>ANZAC Research Institute</td>
<td>Lions Eye Institute</td>
</tr>
<tr>
<td>Asbestos Diseases Research Institute</td>
<td>Ludwig Institute of Cancer Research*</td>
</tr>
<tr>
<td>Australia New Zealand Gynaecological Oncology Group</td>
<td>Macfarlane Burnet Centre for Medical Research</td>
</tr>
<tr>
<td>Australian Regenerative Medicine Institute</td>
<td>Mater Medical Research Institute</td>
</tr>
<tr>
<td>Baker IDI Heart and Diabetes Institute</td>
<td>Melanoma Institute Australia</td>
</tr>
<tr>
<td>Bernard O'Brien Institute of Microsurgery</td>
<td>Murdoch Children's Research Institute</td>
</tr>
<tr>
<td>Bionics Institute of Australia</td>
<td>National Ageing Research Institute</td>
</tr>
<tr>
<td>Black Dog Institute</td>
<td>National Heart Foundation of Australia</td>
</tr>
<tr>
<td>Brien Holden Vision Institute</td>
<td>Neuroscience Research Australia</td>
</tr>
<tr>
<td>Cancer Council NSW</td>
<td>Oxygen Youth Health Research Centre</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Cancer Council Queensland</td>
<td>Parenting Research Centre</td>
</tr>
<tr>
<td>Centenary Institute</td>
<td>Peter MacCallum Cancer Centre</td>
</tr>
<tr>
<td>Centre for Cancer Biology</td>
<td>QIMR Berghofer Medical Research Institute</td>
</tr>
<tr>
<td>Centre for Eye Research Australia</td>
<td>Queensland Children's Medical Research Institute</td>
</tr>
<tr>
<td>Children Youth and Women's Health Service</td>
<td>Queensland Eye Institute</td>
</tr>
<tr>
<td>Children's Cancer Institute Australia</td>
<td>Sax Institute</td>
</tr>
<tr>
<td>Children's Medical Research Institute</td>
<td>Schizophrenia Research Institute</td>
</tr>
<tr>
<td>Ear Science Institute Australia</td>
<td>St Vincent's Institute of Medical Research</td>
</tr>
<tr>
<td>Florey Institute of Neuroscience and Mental Health</td>
<td>Telethon Kids Institute</td>
</tr>
<tr>
<td>Garvan Institute of Medical Research</td>
<td>Trans Tasman Radiation Oncology Group</td>
</tr>
<tr>
<td>George Institute for Global Health</td>
<td>Translational Research Institute</td>
</tr>
<tr>
<td>Harry Perkins Institute of Medical Research</td>
<td>Victor Chang Cardiac Research Institute</td>
</tr>
<tr>
<td>Heart Research Centre</td>
<td>Walter and Eliza Hall Institute of Medical Research</td>
</tr>
<tr>
<td>Heart Research Institute</td>
<td>Wesley Research Institute</td>
</tr>
<tr>
<td>Hudson Institute of Medical Research</td>
<td>Western Australian Neuromuscular Research Institute</td>
</tr>
<tr>
<td>Hunter Medical Research Institute</td>
<td>Westmead Millennium Institute for Medical Research</td>
</tr>
<tr>
<td>Illawarra Health and Medical Research Institute</td>
<td>Women's and Children's Health Research Institute</td>
</tr>
<tr>
<td>Ingham Institute of Applied Medical Research/Kolling Institute of Medical Research</td>
<td>Woolcock Institute of Medical Research</td>
</tr>
<tr>
<td>Institute for Breathing and Sleep</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3: Publicly Funded Research Agencies**

<table>
<thead>
<tr>
<th>Publicly Funded Research Agency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australian Institute of Marine Science</td>
</tr>
<tr>
<td>Australian Nuclear Science and Technology Organisation</td>
</tr>
<tr>
<td>Commonwealth Scientific and Industrial Research Organisation</td>
</tr>
<tr>
<td>Defence Science and Technology Organisation</td>
</tr>
<tr>
<td>National ICT Australia Limited</td>
</tr>
</tbody>
</table>

*Note: The Ludwig Institute of Cancer Research is not included in the report due to difficulties in assigning their patents. This will be rectified in future reports.*
Appendix B: Data sources

IPGOD
The Intellectual Property Government Open Data (IPGOD)\(^{26}\) set includes over 100 years of IP rights administered by IP Australia comprising patents, trade marks, designs and plant breeder’s rights. The data is highly detailed, including information on each aspect of the application process, from application through to granting of IP rights. An important feature of the IPGOD is the ability to match IP administrative data with firm-level business characteristics for Australian companies such as ABN information or entity size.

The IPGOD includes geospatial data such as the state/territory and postcode of the applicant, and a geocode of the applicant address, as well as a marker indicating the quality of the geocoding. We used this data to identify Australian trade marks and designs.

In this project IPGOD was used to determine trade marks, designs and plant breeders rights associated with NSRC recipients. Each applicant in the IPGOD can be identified by their assigned unique identifier which extends across all the different intellectual property rights tables. For example, all of the patents, trade marks and designs owned by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) have the same identifier. If the identifier was not sufficient in identifying the applicant ABN data was used.

PSS
Internal IP Australia administrative data (PSS) is the database on which IPGOD is based, however it includes administrative data relating to IP rights that is not publicly available. We used PSS to determine provisional patent applications.

PATSTAT
PATSTAT is the European Patent Office’s database containing bibliographic data relating to worldwide patent filings with more than 90 million records.\(^{27}\) The type of bibliographic data that this relational database contains includes applicant name, origin, patent filing, classification and publication dates and legal status changes.

PATSTAT was our primary data source for determining patent filings for our applicants.

INPADOC
The EPO worldwide legal status database (INPADOC) contains information on legal events that occurred during the life of a patent, either before or after grant. We used this to determine the status of patents and patent families.

OECD Citations Database
The EPO worldwide legal status database (INPADOC) contains information on legal events that occurred during the life of a patent, either before or after grant. We used this to determine the status of patents and patent families.

The OECD Citations database provides information on patent and non-patent literature (NPL) citations (or references) found in patent documents. Data covers citations made in patents filed at the European Patent Office (EPO) or via the Patent Co-operation Treaty (PCT), and now includes citations made in patents filed at the United States Patent and Trademark Office (USPTO). If the same patent has been published by several patent offices (EPO, WIPO, USPTO, JPO, etc.) any of

\(^{26}\) Government Open Data, [IPGOD 2015](#)
\(^{27}\) European Patent Office, [PATSTAT](#)
the corresponding published document can be cited in patents. For this reason, a table of patent equivalents of the cited patent documents is provided for the three publishing authorities considered. Equivalents help to better account for citations received by particular patents and thus assess, for example, the relative value of inventions.
Appendix C: Methodology

Identification of research organisations

In order to find all the IP rights associated with the research organisations of interest, we aimed to produce a comprehensive list of all the applicant and person identifiers associated with the research organisations in our databases. These included name variations and Australian Business Number (ABN). We then used this data to determine the unique identifier of each of the organisations provided by the Department of Industry, Innovation and Science within IPGOD, PATSTAT and PSS. The unique identifier was cross-referenced in each of the IP databases to retrieve the relevant IP rights.

We attempted to find all name and applicant identifier variations associated with each research organisation and controlled entity, but due to data entry errors it possible not all variations have been located. For instance, data entry errors can cause names to be misspelled in patent records and as such missed during data retrieval.

IPGOD

Where possible, the Australian Business Number (ABN) was used to identify organisations in the firm information tables in IPGOD (tables 102, 202, 302 and 402). This enabled us to find the IPA_APPLICANT_ID(s) associated with each organisation in these tables. The IPA_APPLICANT_ID is an identifier of the group that an applicant belongs to within IPGOD. All applicants with the same identifier are believed to be the same applicant. If the ABN was not provided for the organisation, the organisation names were searched in the Australian Business Register (ABR) to find ABN. If no ABN was found, the research organisation name was searched as applicant name in the firm information tables to identify the IPA_APPLICANT_ID(s). Each applicant name associated with the IPA_APPLICANT_ID(s) was extracted in order to search databases where there are not applicant identifiers present.

PATSTAT

With the name and IPA_APPLICANT_IDs extracted from IPGOD, the Australian patents assigned to the organisations were cross-referenced with entries for the same patents in the PATSTAT database to extract the applicant identifiers and names therein.

PERSON_ID is a stable ID that does not change between different PATSTAT editions. A unique person identifier is assigned in PATSTAT for each unique combination of PERSON_NAME and PERSON_ADDRESS and PERSON_CTRY_CODE. The PERSON_NAME is the name as delivered by the patent office that provides the data to the EPO. A disadvantage of the PERSON_ID is that there will be several PERSON_IDs available for each research organisation but through the capture of all known name variations we hoped to include every PERSON_ID associated with the research organisation.

A stable data structure was develop to store the applicant information extracted from IPGOD and PATSTAT which were then used to find the IP rights associated with each research organisation. This data structure was designed to be reusable for every survey release.
**Patent data**

The data includes all patent information for universities and their technology transfer offices, publicly funded research organisations and medical research institutes, from 1 January 2000 to 31 December 2014 inclusive.

The information regarding provisional patent applications and innovation patents is limited to Australia.

**Table 4: Data sources for patent information**

<table>
<thead>
<tr>
<th>Intellectual Property Right</th>
<th>Databases Accessed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent</td>
<td>PATSTAT</td>
</tr>
<tr>
<td></td>
<td>IPGOD</td>
</tr>
<tr>
<td></td>
<td>PSS</td>
</tr>
</tbody>
</table>

**Granted patents**

Granted patents were determining using the field PUBLN_FIRST_GRANT field in the TLS211_PAT_PUBLN table in PATSTAT. If an application has a publication with PUBLN_FIRST_GRANT = 1 then it can be concluded that the application has been granted. In all other cases, the application is still pending.

Information in regard to EP grants has been included in addition to US and AU grants. This decision was based on the fact that applicants often do not file in European convention counties until the EP application has been granted.

**Filing Location**

All IP rights in IPGOD are filed in Australia.

The PUBLN_AUTH field in PATSTAT table TLS211_PAT_PUBLN was used to determine filing location for other jurisdictions.

**Dates**

In the case of patent grants, the date of publication was used as the filter. In the case of other patent counts the application filing date was used.

**Provisional patents**

Provisional patent applications were retrieved from the internal IP Australia (PSS) database by locating patent application numbers having the PATENT_TYPE of 'Provisional'.

Provisional applications are not published but serve as a means to provide the applicant with a priority date.

**Innovation patents**

Innovation patents were retrieved from the internal IP Australia (PSS) database by locating patent application numbers having the prefix ‘201x1’, where ‘201x’ indicates the year of filing and ‘1’ being dedicated to innovation patents.

Innovation patents are a second tier patent in Australia, similar to utility models used in other jurisdictions.

**PCT applications**

PCTs were identified using APPLN_KIND = 'W' in the TLS201_APPLN table in PATSTAT.
National phase entries

National phase applications, i.e. patent applications lodged in Australia via the PCT route, were searched within IPGOD by identifying those applications that had a patent type of ‘NPE’ or included a national phase entry date that was not null.

Convention applications

Convention applications were identified by subtracting all the NPEs, PCTs and divisionals from the TLS201_APPLN table in PATSTAT, with from the application INTERNAT_APPLN_ID = 0 and a PRIOR_APPLN_ID that was not null, indicating that the application was claiming priority from a prior filing.

Status

The legal event code descriptors from the TLS802_LEGAL_EVENT_CODE table in PATSTAT (part of the INPAODC database) were used to determine whether a patent has lapsed, expired or had been withdrawn. Patents are identified as no longer being in force if in the last year there was a legal status action of 'lapsed' or 'withdrawn' or 'expired'. In the case of a PCT application if more than 3 years had passed and it did not enter the national phase in any of its elected countries the application was considered also to no longer in force.

A patent is considered 'granted' if it has an associated grant (as determined above) and if its most recent PATSTAT legal status code does not indicate that it has been lapsed or withdrawn or expired.

Patent holdings

The total number of holdings were calculated as follows: a patent family was considered 'Pending' if it does not have an associated grant (PUBLN_FIRST_GRANT is 0 in PATSTAT TLS211_PAT_PUBLN) and if its most recent PATSTAT legal status code does not indicate that it has been lapsed or withdrawn or expired. A PCT application is considered 'Pending' for three years after its filing date, to approximate the time period to enter national phase.

The total number of families for which held at least one granted application was still in force were counted for each of the research organisations to determine their holdings.

RSI

The RSI was calculated using Thomson Innovation to determine the primary IPC mark for each application.
Other IP rights data

Trademark, design and plant breeder’s rights data is limited to Australian filings in the period from 1 January 2000 to 31 December 2014 inclusive.

Table 5: Data sources for patent information

<table>
<thead>
<tr>
<th>Intellectual Property Right</th>
<th>Databases Accessed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade mark</td>
<td>IPGOD</td>
</tr>
<tr>
<td>Plant Breeder’s Right</td>
<td>IPGOD</td>
</tr>
<tr>
<td>Industrial Designs</td>
<td>IPGOD</td>
</tr>
</tbody>
</table>

All the trademark, design and plant breeder’s rights information were extracted from the IPGOD firm information tables (IPGOD_202, IPGOD_302 and IPGOD_402) based on either ABN data or IPA_APPLICANT_IDs. Additional filing information was then extracted from IPGOD summary tables (IPGOD_201, IPGOD_301, IPGOD_401).

For PBRs we included additional information about the legal status of the application. A status of ‘granted’ is indicates the PBR has been accepted and ‘received’ indicates that it is pending. Specifically the following status codes were interpreted as:

Table 6: PBR legal status

<table>
<thead>
<tr>
<th>Status</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Received</td>
<td>No examination (yet)</td>
</tr>
<tr>
<td>Accepted</td>
<td>Examined</td>
</tr>
<tr>
<td>Granted</td>
<td>sealed after period for opposition</td>
</tr>
<tr>
<td>Withdrawn</td>
<td>withdrawn by applicant before grant</td>
</tr>
<tr>
<td>Refused</td>
<td>grant refused in examination</td>
</tr>
<tr>
<td>Terminated</td>
<td>withdrawn by applicant after grant</td>
</tr>
<tr>
<td>Expired</td>
<td>Term of PBR is up after grant</td>
</tr>
</tbody>
</table>